Aurinia Pharmaceuticals Inc. Amortization of Intangible Assets
Aurinia Pharmaceuticals Inc. (AUPH) reported Amortization of Intangible Assets of $200.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfIntangibleAssets · last filed 2026-08-06
- Aurinia Pharmaceuticals Inc. amortization of intangible assets for the quarter ending 2026-06-30 was $200.00K, a 0.00% change year-over-year.
- Aurinia Pharmaceuticals Inc. amortization of intangible assets for the quarter ending 2026-03-31 was $200.00K, a 0.00% change year-over-year.
- Aurinia Pharmaceuticals Inc. amortization of intangible assets for the quarter ending 2025-12-31 was $200.00K, a 0.00% change year-over-year.
- Aurinia Pharmaceuticals Inc. amortization of intangible assets for the quarter ending 2025-09-30 was $200.00K, a 0.00% change year-over-year.
- Aurinia Pharmaceuticals Inc. amortization of intangible assets for fiscal 2025 was $800.00K, a 11.11% decline from fiscal 2024.
- Aurinia Pharmaceuticals Inc. amortization of intangible assets for fiscal 2024 was $900.00K, a 47.06% decline from fiscal 2023.
- Aurinia Pharmaceuticals Inc. amortization of intangible assets for fiscal 2023 was $1.70M, a 19.05% decline from fiscal 2022.
- Aurinia Pharmaceuticals Inc. amortization of intangible assets for fiscal 2022 was $2.10M, a 0.00% change from fiscal 2021.
| Period end | Amortization of Intangible Assets 3 month | Amortization of Intangible Assets 3 month as first filed | Amortization of Intangible Assets 6 month | Amortization of Intangible Assets 6 month as first filed | Amortization of Intangible Assets 9 month | Amortization of Intangible Assets 9 month as first filed | Amortization of Intangible Assets 12 month | Amortization of Intangible Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $200.00K 10-Q · filed 2026-08-06 | $400.00K 10-Q · filed 2026-08-06 | $600.00K derived: sum of 3 quarters · filed 2026-08-06 | $800.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-07 | $400.00K derived: sum of 2 quarters · filed 2026-05-07 | $600.00K derived: sum of 3 quarters · filed 2026-05-07 | $800.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $400.00K derived: sum of 2 quarters · filed 2026-02-26 | $600.00K derived: sum of 3 quarters · filed 2026-08-06 | $800.00K 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $200.00K 10-Q · filed 2025-11-04 | $400.00K derived: sum of 2 quarters · filed 2026-08-06 | $600.00K 10-Q · filed 2025-11-04 | $800.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $200.00K 10-Q · filed 2026-08-06 | $400.00K 10-Q · filed 2026-08-06 | $600.00K derived: sum of 3 quarters · filed 2026-08-06 | $800.00K derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $200.00K 10-Q · filed 2026-05-07 | $400.00K derived: sum of 2 quarters · filed 2026-05-07 | $600.00K derived: sum of 3 quarters · filed 2026-05-07 | $800.00K derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $400.00K derived: sum of 2 quarters · filed 2026-02-26 | $600.00K derived: sum of 3 quarters · filed 2026-02-26 | $900.00K 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $200.00K 10-Q · filed 2025-11-04 | $400.00K derived: sum of 2 quarters · filed 2025-11-04 | $700.00K 10-Q · filed 2025-11-04 | $900.00K derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $200.00K 10-Q · filed 2025-07-31 | $500.00K 10-Q · filed 2025-07-31 | $700.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.20M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $200.00K 10-Q · filed 2025-05-12 | $500.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.00M derived: sum of 3 quarters · filed 2026-02-26 | $1.50M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $800.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.30M derived: sum of 3 quarters · filed 2026-02-26 | $1.70M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $500.00K 10-Q · filed 2024-11-07 | $1.00M derived: sum of 2 quarters · filed 2024-11-07 | $1.40M 10-Q · filed 2024-11-07 | $2.00M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2023-06-30 | $500.00K 10-Q · filed 2024-08-01 | $900.00K 10-Q · filed 2024-08-01 | $1.00M 10-Q · filed 2023-08-03 | $1.50M derived: sum of 3 quarters · filed 2025-02-27 | $2.00M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | $500.00K 10-Q · filed 2024-05-02 | $1.00M derived: sum of 2 quarters · filed 2025-02-27 | $1.50M derived: sum of 3 quarters · filed 2025-02-27 | $2.00M derived: sum of 4 quarters · filed 2025-02-27 | ||||
| 2022-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.00M derived: sum of 2 quarters · filed 2025-02-27 | $1.50M derived: sum of 3 quarters · filed 2025-02-27 | $2.10M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $500.00K 10-Q · filed 2023-11-02 | $1.00M derived: sum of 2 quarters · filed 2023-11-02 | $1.60M 10-Q · filed 2023-11-02 | $2.00M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-06-30 | $500.00K 10-Q · filed 2023-08-03 | $1.00M 10-Q · filed 2023-08-03 | $1.50M derived: sum of 3 quarters · filed 2024-02-15 | $2.00M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2022-03-31 | $500.00K 10-Q · filed 2023-05-04 | $1.00M derived: sum of 2 quarters · filed 2024-02-15 | $1.50M derived: sum of 3 quarters · filed 2024-02-15 | $2.00M derived: sum of 4 quarters · filed 2024-02-15 | ||||
| 2021-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $1.00M derived: sum of 2 quarters · filed 2024-02-15 | $1.50M derived: sum of 3 quarters · filed 2024-02-15 | $2.10M 10-K · filed 2024-02-15 | $2.10M 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $500.00K 10-Q · filed 2022-11-03 | $517.00K 10-Q · filed 2021-11-03 | $1.00M derived: sum of 2 quarters · filed 2022-11-03 | $1.60M 10-Q · filed 2022-11-03 | $1.58M 10-Q · filed 2021-11-03 | $1.90M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-06-30 | $500.00K 10-Q · filed 2022-08-04 | $536.00K 10-Q · filed 2021-08-05 | $1.10M 10-Q · filed 2022-08-04 | $1.06M 10-Q · filed 2021-08-05 | $1.40M derived: sum of 3 quarters · filed 2023-02-28 | $1.71M derived: sum of 4 quarters · filed 2023-02-28 | ||
| 2021-03-31 | $500.00K 10-Q · filed 2022-05-10 | $523.00K 10-Q · filed 2021-05-06 | $898.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.21M derived: sum of 3 quarters · filed 2023-02-28 | $1.51M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | $398.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $714.00K derived: sum of 2 quarters · filed 2023-02-28 | $1.01M derived: sum of 3 quarters · filed 2023-02-28 | $1.30M 10-K · filed 2023-02-28 | $1.29M 10-K · filed 2021-02-24 | |||
| 2020-09-30 | $316.00K 10-Q · filed 2021-11-03 | $616.00K derived: sum of 2 quarters · filed 2021-11-03 | $902.00K 10-Q · filed 2021-11-03 | |||||
| 2020-06-30 | $300.00K 10-Q · filed 2021-08-05 | $586.00K 10-Q · filed 2021-08-05 | ||||||
| 2020-03-31 | $286.00K 10-Q · filed 2021-05-06 | |||||||
| 2019-12-31 | $1.14M 10-K · filed 2022-02-28 | |||||||
| 2018-12-31 | $1.29M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |